Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Investing.com -- Shares of Merck KGaA (ETR: MRCG) fell over 4% on Thursday following a mixed reception to its third-quarter ...

Bernstein has recently initiated Merck & Co Inc (MRK) stock to Mkt Perform rating, as announced on October 17, 2024, according to Finviz. Earlier, on March 11, 2024, Societe Generale had reduced the ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

Shares of Merck & Co. Inc. MRK inched 0.44% higher to $101.17 Thursday, on what proved to be an all-around mixed trading ...

In my view, based on what's coming up for Merck, it's likely that investors with some patience will find the stock to be more ...

Deadly fungi including Candida auris have been spreading. Gilead and Merck are two pharma stocks worth owning amidst fungal ...

Immutep's American depositary receipts jumped after the company reported positive data from a trial evaluating its drug Efti in combination with Merck's therapy Keytruda for treating non-small cell ...

In my view, based on what's coming up for Merck, it's likely that investors with some patience will find the stock to be more appealing. Understanding the investment thesis for Merck requires ...